Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Administrative metadata on the study record was updated between the screenshots. No modifications to the trial's objectives, eligibility criteria, dosing, endpoints, or enrollment were observed.
    Difference
    0.4%
    Check dated 2025-11-03T21:32:53.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    43 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and updated operating-status guidance, plus version bump to v3.2.0; removed the previous v3.1.0 tag.
    Difference
    2%
    Check dated 2025-10-06T08:12:20.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T04:37:07.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Updated to revision v3.0.2 (replacing v3.0.1) and removed the Back to Top element. This is a minor maintenance update with no changes to core content, pricing, stock, or time-sensitive information.
    Difference
    0.1%
    Check dated 2025-09-14T22:20:27.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-07T19:36:39.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, while several related medical topics and terms have been removed, including specific drug names and classifications.
    Difference
    3%
    Check dated 2025-08-31T12:26:50.000Z thumbnail image

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.